Skip to Content

Temozolomide Pregnancy and Breastfeeding Warnings

Temozolomide is also known as: Temodar

Temozolomide Pregnancy Warnings

Animal studies have shown teratogenicity at doses higher than the maximum dose used clinically. Fetal malformations of the external organs, soft tissues, and skeleton occurred. Embryolethality occurred in animal studies as indicated by increased resorptions. There are no controlled data in human pregnancy. Male patients should be advised to seek advice regarding cryopreservation of sperm prior to treatment due to the possibility of irreversible infertility. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

AU: Use is contraindicated in women who are pregnant or contemplating pregnancy. US and UK: Use is not recommended in women who are pregnant or contemplating pregnancy. AU TGA pregnancy category: D US FDA pregnancy category: D Comments: Encourage use of adequate methods of contraception in male and female patients during treatment and for at least 6 months following the last dose.

See references

Temozolomide Breastfeeding Warnings

AU: Use is contraindicated. UK and US: Breastfeeding is not recommended during use of this drug. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Temodar (temozolomide)" Schering Corporation, Kenilworth, NJ.

References for breastfeeding information

  1. "Product Information. Temodar (temozolomide)" Schering Corporation, Kenilworth, NJ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.